A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Trial Details

NCT ID
NCT05086692
Phase
PHASE1 / PHASE2
Sponsor
Medicenna Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • San Diego, California, United States|32.71571,-117.16472
  • San Francisco, California, United States|37.77493,-122.41942
  • Santa Monica, California, United States|34.01949,-118.49138
  • Boca Raton, Florida, United States|26.35869,-80.0831
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Aged at least 18 years (inclusive at the time of informed consent).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
  • Must be able and willing to provide written informed consent prior to start of any study procedures and assessments and must be willing to comply w…
  • Histologically or cytologically confirmed locally advanced or metastatic solid tumor (see tumor types listed under conditions)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →